Their lead drug candidate, ST-001 nanoFenretinide, is a patented combination of their SDP and the cancer drug fenretinide, designed to treat diseases with limited therapeutic options. The company's drugs contain nanoparticle fenretinide formulation with immunotherapy effects, enabling medical practitioners to treat their patients with effective medications. SciTech Development aims to commercialize ST-001 and develop strategic partnerships with pharmaceutical companies to expand their existing drug portfolio in oncology, target new diseases, or develop combination drug therapies. They have achieved FDA approval for Phase 1a/b clinical trials, IRB approval from Rush University Medical Center, and Orphan Drug Designation for several T-cell lymphomas. Their SDP has potential applications for treating additional cancers and other diseases, and ST-001 has potential use as a companion therapeutic with other already approved drugs, with an affordable treatment cost to patients and payors.